Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-04-28

FDA Approved: BUPRENORPHINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

FDA approved a supplemental application for buprenorphine from Teva Pharmaceuticals USA, Inc. under ANDA204937.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • buprenorphine (buprenorphine)

Snippet

SUPPL AP for BUPRENORPHINE (BUPRENORPHINE)